|
5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI, or Chaperon) is a psychoactive small molecule belonging to the aminoindane class with a mechanism of action described by one patent as being mediated by binding to the dopamine D3 receptor.〔(【引用サイトリンク】first1=Susanne )〕 It was first prepared by Schering AG in 1956.〔(Verfahren zur Herstellung von analgetisch wirksamen 2-Aminoindanverbindungen ), German Patent DE952441, Nov. 15, 1956〕 David Nutt and Amanda Feilding filed a patent application for the drug claiming that it gives people a pleasant intoxication as well as prevent binge drinking. MEAI has been available through grey market sources since 2011.〔(【引用サイトリンク】 title=5-Meo-AI )〕 At least 2 journalists tried it on themselves and reported to the public: Michael Slezak from New Scientist〔(【引用サイトリンク】first1=Michael )〕 and Brie Traits from BBC3. Apparently, Nutt has also tried it himself. The idea of alcohol substitution got public attention a year prior to the announcement of chaperon but apparently, chaperon innovates in that it can be consumed together with alcohol without ill effect. MEAI is banned in some countries as a structural isomer of methcathinone. ==See also== * 2-AI * AMMI * MMAI * MDAI * NM-2-AI 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「MEAI」の詳細全文を読む スポンサード リンク
|